MARK MITTAUER: Open Payments
NPI 1255322996 · GROTON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,018 in 130 payments from 13 companies in 2025. Trend: 2023 $901 · 2024 $1,058 · 2025 $2,018
Food & beverage: $2,018
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $501 |
| Neurocrine BioSciences, Inc. | 36 | $324 |
| Otsuka America Pharmaceutical, Inc. | 16 | $301 |
| Janssen Pharmaceuticals, Inc | 13 | $191 |
| Alkermes, Inc. | 12 | $178 |
| Teva Pharmaceuticals USA, Inc. | 8 | $154 |
| Vanda Pharmaceuticals Inc. | 5 | $106 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $105 |
| Axsome Therapeutics, Inc. | 3 | $46 |
| Collegium Pharmaceutical, Inc. | 3 | $45 |
Products named: VRAYLAR, INGREZZA, REXULTI, ARISTADA, INVEGA SUSTENNA, FANAPT, CAPLYTA, SPRAVATO.
Industry payments across CT — which companies pay providers there.
